HMMR (hyaluronan mediated motility receptor)

2003-02-01  

Identity

HGNC
LOCATION
5q34
LOCUSID
ALIAS
CD168,IHABP,RHAMM
FUSION GENES

Other Information

Locus ID:

NCBI: 3161
MIM: 600936
HGNC: 5012
Ensembl: ENSG00000072571

Variants:

dbSNP: 3161
ClinVar: 3161
TCGA: ENSG00000072571
COSMIC: HMMR

RNA/Proteins

Gene IDTranscript IDUniprot
ENSG00000072571ENST00000353866O75330
ENSG00000072571ENST00000358715O75330
ENSG00000072571ENST00000393915O75330
ENSG00000072571ENST00000432118O75330
ENSG00000072571ENST00000520345E5RI30
ENSG00000072571ENST00000522094E5RIH2

Expression (GTEx)

0
10
20
30
40
50
60

Pathways

PathwaySourceExternal ID
ECM-receptor interactionKEGGko04512
ECM-receptor interactionKEGGhsa04512
Cell CycleREACTOMER-HSA-1640170
Cell Cycle, MitoticREACTOMER-HSA-69278
Mitotic G2-G2/M phasesREACTOMER-HSA-453274
G2/M TransitionREACTOMER-HSA-69275
MetabolismREACTOMER-HSA-1430728
Metabolism of carbohydratesREACTOMER-HSA-71387
Glycosaminoglycan metabolismREACTOMER-HSA-1630316
Hyaluronan metabolismREACTOMER-HSA-2142845
Hyaluronan uptake and degradationREACTOMER-HSA-2160916
AURKA Activation by TPX2REACTOMER-HSA-8854518

Protein levels (Protein atlas)

Not detected
Low
Medium
High

PharmGKB

Entity IDNameTypeEvidenceAssociationPKPDPMIDs
PA128406956fluorouracilChemicalClinicalAnnotation, VariantAnnotationassociatedPD
PA443560Breast NeoplasmsDiseaseClinicalAnnotation, VariantAnnotationassociatedPD
PA445113NeutropeniaDiseaseClinicalAnnotation, VariantAnnotationassociatedPD
PA449165cyclophosphamideChemicalClinicalAnnotation, VariantAnnotationassociatedPD
PA449476epirubicinChemicalClinicalAnnotation, VariantAnnotationassociatedPD

References

Pubmed IDYearTitleCitations
179220142007Network modeling links breast cancer susceptibility and centrosome dysfunction.263
243670992014Interplay of mevalonate and Hippo pathways regulates RHAMM transcription via YAP to modulate breast cancer cell motility.119
183540822008Cell-surface and mitotic-spindle RHAMM: moonlighting or dual oncogenic functions?85
173922722007The hyaluronan receptors CD44 and Rhamm (CD168) form complexes with ERK1,2 that sustain high basal motility in breast cancer cells.79
179781702008RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma elicits immunologic and clinical responses.62
189716362008RHAMM is differentially expressed in the cell cycle and downregulated by the tumor suppressor p53.41
173958882007Apical oxidative hyaluronan degradation stimulates airway ciliary beating via RHAMM and RON.38
122257942002Receptor for hyaluronan acid-mediated motility (RHAMM) is a new immunogenic leukemia-associated antigen in acute and chronic myeloid leukemia.37
221104032011Interplay between BRCA1 and RHAMM regulates epithelial apicobasal polarization and may influence risk of breast cancer.37
157058832005Receptor for hyaluronan-mediated motility correlates with centrosome abnormalities in multiple myeloma and maintains mitotic integrity.33

Citation

Dessen P

HMMR (hyaluronan mediated motility receptor)

Atlas Genet Cytogenet Oncol Haematol. 2003-02-01

Online version: http://atlasgeneticsoncology.org/gene/40837/hmmr